000286099 001__ 286099
000286099 005__ 20240423102733.0
000286099 0247_ $$2doi$$a10.1200/JCO.23.01101
000286099 0247_ $$2pmid$$apmid:38079601
000286099 0247_ $$2ISSN$$a0732-183X
000286099 0247_ $$2ISSN$$a1527-7755
000286099 0247_ $$2altmetric$$aaltmetric:157397664
000286099 037__ $$aDKFZ-2023-02675
000286099 041__ $$aEnglish
000286099 082__ $$a610
000286099 1001_ $$00000-0002-8761-582X$$aTimmins, Iain R$$b0
000286099 245__ $$aInternational Pooled Analysis of Leisure-Time Physical Activity and Premenopausal Breast Cancer in Women From 19 Cohorts.
000286099 260__ $$aAlexandria, Va.$$bAmerican Society of Clinical Oncology$$c2024
000286099 3367_ $$2DRIVER$$aarticle
000286099 3367_ $$2DataCite$$aOutput Types/Journal article
000286099 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1713860805_6082
000286099 3367_ $$2BibTeX$$aARTICLE
000286099 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000286099 3367_ $$00$$2EndNote$$aJournal Article
000286099 500__ $$a2024 Mar 10;42(8):927-939
000286099 520__ $$aThere is strong evidence that leisure-time physical activity is protective against postmenopausal breast cancer risk but the association with premenopausal breast cancer is less clear. The purpose of this study was to examine the association of physical activity with the risk of developing premenopausal breast cancer.We pooled individual-level data on self-reported leisure-time physical activity across 19 cohort studies comprising 547,601 premenopausal women, with 10,231 incident cases of breast cancer. Multivariable Cox regression was used to estimate hazard ratios (HRs) and 95% CIs for associations of leisure-time physical activity with breast cancer incidence. HRs for high versus low levels of activity were based on a comparison of risk at the 90th versus 10th percentiles of activity. We assessed the linearity of the relationship and examined subtype-specific associations and effect modification across strata of breast cancer risk factors, including adiposity.Over a median 11.5 years of follow-up (IQR, 8.0-16.1 years), high versus low levels of leisure-time physical activity were associated with a 6% (HR, 0.94 [95% CI, 0.89 to 0.99]) and a 10% (HR, 0.90 [95% CI, 0.85 to 0.95]) reduction in breast cancer risk, before and after adjustment for BMI, respectively. Tests of nonlinearity suggested an approximately linear relationship (Pnonlinearity = .94). The inverse association was particularly strong for human epidermal growth factor receptor 2-enriched breast cancer (HR, 0.57 [95% CI, 0.39 to 0.84]; Phet = .07). Associations did not vary significantly across strata of breast cancer risk factors, including subgroups of adiposity.This large, pooled analysis of cohort studies adds to evidence that engagement in higher levels of leisure-time physical activity may lead to reduced premenopausal breast cancer risk.
000286099 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000286099 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000286099 7001_ $$aJones, Michael E$$b1
000286099 7001_ $$00000-0003-0643-3790$$aO'Brien, Katie M$$b2
000286099 7001_ $$00000-0001-9592-5791$$aAdami, Hans-Olov$$b3
000286099 7001_ $$00000-0002-4533-1722$$aAune, Dagfinn$$b4
000286099 7001_ $$00000-0002-8193-7529$$aBaglietto, Laura$$b5
000286099 7001_ $$00000-0002-4565-7618$$aBertrand, Kimberly A$$b6
000286099 7001_ $$00000-0003-0084-4775$$aBrantley, Kristen D$$b7
000286099 7001_ $$aChen, Yu$$b8
000286099 7001_ $$00000-0002-2298-3146$$aClague DeHart, Jessica$$b9
000286099 7001_ $$00000-0003-4170-6977$$aClendenen, Tess V$$b10
000286099 7001_ $$00000-0003-2716-5748$$aDossus, Laure$$b11
000286099 7001_ $$00000-0002-3961-6609$$aEliassen, A Heather$$b12
000286099 7001_ $$00000-0001-9387-7116$$aFletcher, Olivia$$b13
000286099 7001_ $$00000-0001-8380-3439$$aFournier, Agnès$$b14
000286099 7001_ $$00000-0001-7673-5554$$aHåkansson, Niclas$$b15
000286099 7001_ $$aHankinson, Susan E$$b16
000286099 7001_ $$00000-0002-5268-0242$$aHoulston, Richard S$$b17
000286099 7001_ $$00000-0002-5100-172X$$aJoshu, Corinne E$$b18
000286099 7001_ $$00000-0003-2422-2225$$aKirsh, Victoria A$$b19
000286099 7001_ $$00000-0001-6416-4432$$aKitahara, Cari M$$b20
000286099 7001_ $$aKoh, Woon-Puay$$b21
000286099 7001_ $$00000-0002-1687-5587$$aLinet, Martha S$$b22
000286099 7001_ $$00000-0001-9973-1396$$aPark, Hannah Lui$$b23
000286099 7001_ $$00000-0001-8060-547X$$aLynch, Brigid M$$b24
000286099 7001_ $$00000-0003-0643-3790$$aMay, Anne M$$b25
000286099 7001_ $$00000-0001-9222-6215$$aMellemkjær, Lene$$b26
000286099 7001_ $$00000-0001-5764-7268$$aMilne, Roger L$$b27
000286099 7001_ $$00000-0002-6534-335X$$aPalmer, Julie R$$b28
000286099 7001_ $$aRicceri, Fulvio$$b29
000286099 7001_ $$aRohan, Thomas E$$b30
000286099 7001_ $$00000-0001-6298-332X$$aRuddy, Kathryn J$$b31
000286099 7001_ $$00000-0003-4817-0757$$aSánchez, Maria-Jose$$b32
000286099 7001_ $$00000-0002-0711-8314$$aShu, Xiao-Ou$$b33
000286099 7001_ $$aSmith-Byrne, Karl$$b34
000286099 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b35$$udkfz
000286099 7001_ $$00000-0002-7516-9543$$aSund, Malin$$b36
000286099 7001_ $$00000-0002-1962-9322$$aVachon, Celine M$$b37
000286099 7001_ $$00000-0003-2333-5252$$aVatten, Lars J$$b38
000286099 7001_ $$00000-0002-0582-8005$$aVisvanathan, Kala$$b39
000286099 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b40
000286099 7001_ $$00000-0003-1458-7597$$aWillett, Walter C$$b41
000286099 7001_ $$00000-0001-7387-6845$$aWolk, Alicja$$b42
000286099 7001_ $$aYuan, Jian-Min$$b43
000286099 7001_ $$00000-0003-1226-070X$$aZheng, Wei$$b44
000286099 7001_ $$00000-0003-0972-1560$$aNichols, Hazel B$$b45
000286099 7001_ $$00000-0002-6776-0018$$aSandler, Dale P$$b46
000286099 7001_ $$aSwerdlow, Anthony J$$b47
000286099 7001_ $$aSchoemaker, Minouk J$$b48
000286099 773__ $$0PERI:(DE-600)2005181-5$$a10.1200/JCO.23.01101$$gp. JCO.23.01101$$n8$$p927-939$$tJournal of clinical oncology$$v42$$x0732-183X$$y2024
000286099 909CO $$ooai:inrepo02.dkfz.de:286099$$pVDB
000286099 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b35$$kDKFZ
000286099 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000286099 9141_ $$y2023
000286099 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-22$$wger
000286099 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000286099 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-22
000286099 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000286099 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000286099 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000286099 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000286099 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000286099 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000286099 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN ONCOL : 2022$$d2023-10-22
000286099 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000286099 915__ $$0StatID:(DE-HGF)9940$$2StatID$$aIF >= 40$$bJ CLIN ONCOL : 2022$$d2023-10-22
000286099 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000286099 980__ $$ajournal
000286099 980__ $$aVDB
000286099 980__ $$aI:(DE-He78)C110-20160331
000286099 980__ $$aUNRESTRICTED